Catalyst Pharmaceutical Partners, Inc. today announced that Douglas Winship, Vice President of Regulatory Operations, will present top-line safety and efficacy results from Catalyst’s Phase 3 FirdapseTM trial at the 139th Annual Meeting of the American Neurological Association being held at The Baltimore Waterfront Marriott, October 12-14. The presentation, entitled, “A Phase 3 Trial of Firdapse™ Tablets in Lambert-Eaton Myasthenic Syndrome,” to be delivered at the Neuromuscular Disease Special Interest Symposia, is scheduled for Sunday, October 12th at 5:20 pm (EDT).

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=875162

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will present at the 13th Annual BIO Investor Forum being held at The Palace Hotel in San Francisco, California, October 7-8.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=874272

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment
  • Treatment with Firdapse achieved statistical significance for both co-primary clinical endpoints
  • Catalyst expects to initiate rolling NDA submission in early-2015
  • Conference call tomorrow, September 30 at 8:30am EDT

Catalyst Pharmaceutical Partners, Inc., (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced positive top-line results from the pivotal Phase 3 clinical trial of Firdapse™ (amifampridine phosphate tablets equivalent to 10 mg amifampridine) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). Both co-primary endpoints, quantitative myasthenia gravis score (QMG) and subject global impression (SGI), demonstrated that Firdapse was significantly superior to placebo, as did a secondary endpoint for the physician’s clinical global impression of improvement (CGI-I).

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=873552

 

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. announced the appointment of David D. Muth to the newly created position, Executive Vice President, Corporate Development. Mr. Muth will report to Patrick McEnany, Chairman, President and Chief Executive Officer of Catalyst. As Executive Vice President, Corporate Development, Mr. Muth will be responsible for all of Catalyst’s corporate development activities and will work closely with the other members of the Catalyst team in preparing a commercialization strategy for Firdapse™.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=869114

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc.  announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw’s 16th Annual Global Investment Conference, which is being held on September 8-10, 2014 at The Palace Hotel in New York, NY.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=868808

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Brain GABA Levels, a potential surrogate marker of efficacy, will also be followed

Catalyst Pharmaceutical Partners, Inc. announced the initiation of its second Phase 1 safety and tolerance study for CPP-115, a novel GABA aminotransferase (GABA-AT) inhibitor.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=868500

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst Pharmaceutical Partners, Inc. reported financial results for the second quarter and six months ended June 30, 2014.

Read the release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=866227

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Last Patient Completes 2-Week, Blinded Primary Treatment Period – Top-Line Data on Track to Report in 3Q14

100% of Patients Elected to Continue in 2-Year Open Label Follow-up Period

Catalyst Pharmaceutical Partners, Inc. provided an update on the progress of its Phase 3 study of FirdapseTM (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). The last patient has completed the blinded portion of the study and top-line data remains on track to be reported later this quarter. A total of 38 patients completed the 3 month treatment period and were successfully randomized to either receive FirdapseTM or placebo. All patients who were randomized elected to continue in 2-year open label follow-up.

Read release here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=865474

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst today announced it will be presenting at the JMP Securities 2014 Healthcare Conference, in New York. Senior Management will provide an overview of the Company and its key programs on Tuesday, June 24th at 12:30 pm ET. The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.

http://bit.ly/1qvkFLc

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment

Catalyst is set to join the Russell Microcap® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.2 trillion in assets are benchmarked to the Russell Indexes.

http://bit.ly/1pi60RN

DISCLAIMER: Catalyst Pharmaceutical Partners, Inc. (Catalyst) is covered by the analysts at various brokerage firms that issue reports on the company.  Please note that any opinions, estimates or forecasts regarding Catalyst’s performance, clinical trials, company, management, competitors, forecasts made by these analysts are theirs alone and do not represent opinions, estimates or forecasts of Catalyst or its management. Catalyst does not by its reference above or distribution imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations provided by analysts.

Leave a comment
Follow

Get every new post delivered to your Inbox.

Join 216 other followers

%d bloggers like this: